{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T04:15:45Z","timestamp":1758946545100,"version":"3.37.3"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2018,1,15]],"date-time":"2018-01-15T00:00:00Z","timestamp":1515974400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2018,1,15]],"date-time":"2018-01-15T00:00:00Z","timestamp":1515974400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100000133","name":"Agency for Healthcare Research and Quality.","doi-asserted-by":"crossref","award":["R01-HS018956"],"award-info":[{"award-number":["R01-HS018956"]}],"id":[{"id":"10.13039\/100000133","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2018,5]]},"DOI":"10.1007\/s00277-018-3238-4","type":"journal-article","created":{"date-parts":[[2018,1,14]],"date-time":"2018-01-14T23:09:33Z","timestamp":1515971373000},"page":"851-863","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Risk of adverse events associated with front-line anti-myeloma treatment in Medicare patients with multiple myeloma"],"prefix":"10.1007","volume":"97","author":[{"given":"Ying","family":"Chen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David R.","family":"Lairson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenyaw","family":"Chan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xianglin L.","family":"Du","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,1,15]]},"reference":[{"key":"3238_CR1","unstructured":"Howlader N, Noone AM, Krapcho M, et al (eds) (2015) SEER Cancer Statistics Review, 1975-2012, National Cancer Institute. Bethesda, MD. \n                    http:\/\/seer.cancer.gov\/csr\/1975_2012\/\n                    \n                  , based on November 2014 SEER data submission, posted to the SEER web site, April 2015"},{"key":"3238_CR2","unstructured":"American Cancer Society. Available at \n                    http:\/\/www.cancer.org\/cancer\/multiplemyeloma\/detailedguide\/multiple-myeloma-key-statistics\n                    \n                  . Accessed September 2016"},{"issue":"5","key":"3238_CR3","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1046\/j.1365-2141.2003.04355.x","volume":"121","author":"International Myeloma Working Group","year":"2003","unstructured":"International Myeloma Working Group (2003) Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the international myeloma working group. Br J Haematol 121(5):749\u2013757. \n                    https:\/\/doi.org\/10.1046\/j.1365-2141.2003.04355.x","journal-title":"Br J Haematol"},{"issue":"Suppl 1","key":"3238_CR4","doi-asserted-by":"crossref","first-page":"S125","DOI":"10.1179\/102453312X13336169156339","volume":"17","author":"RA Kyle","year":"2012","unstructured":"Kyle RA (2012) Targeted therapy of multiple myeloma. Hematology 17(Suppl 1):S125\u2013S128","journal-title":"Hematology"},{"issue":"4","key":"3238_CR5","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1016\/j.mayocp.2013.01.019","volume":"88","author":"JR Mikhael","year":"2013","unstructured":"Mikhael JR, Dingli D, Roy V, Reeder CB, Buadi FK, Hayman SR et al (2013) Management of newly diagnosed symptomatic multiple myeloma: updated Mayo stratification of myeloma and risk-adapted therapy (mSMART) consensus guidelines 2013. Mayo Clin Proc 88(4):360\u2013376. \n                    https:\/\/doi.org\/10.1016\/j.mayocp.2013.01.019","journal-title":"Mayo Clin Proc"},{"issue":"4","key":"3238_CR6","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1200\/JCO.2011.37.8919","volume":"30","author":"KC Anderson","year":"2012","unstructured":"Anderson KC (2012) The 39th David A. Karnofsky lecture: bench-to-bedside translation of targeted therapies in multiple myeloma. J Clin Oncol 30(4):445\u2013452. \n                    https:\/\/doi.org\/10.1200\/JCO.2011.37.8919","journal-title":"J Clin Oncol"},{"key":"3238_CR7","doi-asserted-by":"crossref","unstructured":"S O\u2019Brien, Vose JM, Kantarjian HM (2010) Management of hematologic malignancies. Cambridge University Press","DOI":"10.1017\/CBO9780511781926"},{"issue":"9758","key":"3238_CR8","doi-asserted-by":"publisher","first-page":"2075","DOI":"10.1016\/S0140-6736(10)61424-9","volume":"376","author":"M Cavo","year":"2010","unstructured":"Cavo M, Tacchetti P et al (2010) Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, doublet autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomized phase 3 study. Lancet 376(9758):2075\u20132085","journal-title":"Lancet"},{"issue":"4","key":"3238_CR9","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1182\/blood-2010-02-268862","volume":"126","author":"PG Richardson","year":"2010","unstructured":"Richardson PG, Weller E et al (2010) Lenalidomide, bortezomib, and dexamethasone combiantion therpay in patients with newly diagnosed multiple meyloma. Blood 126(4):679\u2013686","journal-title":"Blood"},{"key":"3238_CR10","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1182\/blood.V126.23.25.25","volume":"126","author":"B Durie","year":"2015","unstructured":"Durie B, Hoering A et al (2015) Bortezomib, lenalidomide and dexamethasone vs. lenalidomide and dexamethasone in patients with previously untreated multiple myeloma without an intent for immediate autologous stem cell transplant (ASCT): results of the randomized phase III trial SWOG S0777. Blood 126:25","journal-title":"Blood"},{"key":"3238_CR11","unstructured":"National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology (NCCN guidelines) version 1.2012, National Comprehensive Cancer Network"},{"issue":"Suppl 6","key":"3238_CR12","doi-asserted-by":"publisher","first-page":"vi133","DOI":"10.1093\/annonc\/mdt297","volume":"24","author":"J Moreau","year":"2013","unstructured":"Moreau J, San Miguel J et al (2013) Multiple myeloma: ESMO clinical practice guidelines. Ann Oncol 24(Suppl 6):vi133\u2013vi137","journal-title":"Ann Oncol"},{"issue":"4","key":"3238_CR13","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.blre.2011.03.005","volume":"25","author":"A Palumbo","year":"2011","unstructured":"Palumbo A, Mateos MV, Bringhen S, San Miguel JF (2011 Jul) Practical management of adverse events in multiple myeloma: can therapy be attenuated in older patients? Blood Rev 25(4):181\u2013191. \n                    https:\/\/doi.org\/10.1016\/j.blre.2011.03.005","journal-title":"Blood Rev"},{"issue":"2","key":"3238_CR14","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1177\/2040620711432020","volume":"3","author":"MV Mateos","year":"2012","unstructured":"Mateos MV, San Miquel JF (2012) Safety and efficacy of subcutaneous formulation of bortezomib versus the conventional intravenous formulation in multiple myeloma. Ther Adv Hematol 3(2):117\u2013124","journal-title":"Ther Adv Hematol"},{"issue":"3","key":"3238_CR15","first-page":"194","volume":"1","author":"IM Ghobrial","year":"2012","unstructured":"Ghobrial IM, Rajkumar SV (2012) Management of thalidomide toxicity. J Support Oncol 1(3):194\u2013205","journal-title":"J Support Oncol"},{"issue":"4","key":"3238_CR16","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1038\/leu.2011.346","volume":"26","author":"PG Richardson","year":"2012","unstructured":"Richardson PG, Delforge M, Beksac M, Wen P et al (2012) Management of treatment-emergent peripheral neuropathy in multiple myeloma. Leukemia 26(4):595\u2013608. \n                    https:\/\/doi.org\/10.1038\/leu.2011.346","journal-title":"Leukemia"},{"issue":"33","key":"3238_CR17","doi-asserted-by":"publisher","first-page":"3921","DOI":"10.1200\/JCO.2014.58.7618","volume":"33","author":"R Miesvizky","year":"2015","unstructured":"Miesvizky R, Flinn IW, Rifkin R, Gabrail N et al (2015) Community-based phase IIIB trial of three UPFRONT Bortezomib-based myeloma regimens. J Clin Oncol 33(33):3921\u20133929. \n                    https:\/\/doi.org\/10.1200\/JCO.2014.58.7618","journal-title":"J Clin Oncol"},{"issue":"1","key":"3238_CR18","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1097\/JTO.0b013e3181c0a128","volume":"5","author":"D Hardy","year":"2010","unstructured":"Hardy D, Cormier JN, Xing Y, Liu CC, Xia R, Du XL (2010 Jan) Chemotherapy-associated toxicity in a large cohort of elderly patients with non-small cell lung cancer. J Thorac Oncol 5(1):90\u201398. \n                    https:\/\/doi.org\/10.1097\/JTO.0b013e3181c0a128","journal-title":"J Thorac Oncol"},{"key":"3238_CR19","unstructured":"Cunningham J, Ries L, Hankey B, et al (1992) National Cancer Institute (U.S.). Surveillance program, SEER program (National Cancer Institute (U.S.). The SEER program code manual. Revised edition. Bethesda: Cancer Statistic Branch, National Cancer Institute, National Institute of Health"},{"key":"3238_CR20","unstructured":"National Cancer Institute. Brochure for the SEER program available at \n                    http:\/\/seer.cancer.gov\/about\/factsheets\/SEER_brochure.pdf. Accessed September 2016"},{"issue":"8","key":"3238_CR21","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1097\/00005650-199308000-00006","volume":"31","author":"AL Potosky","year":"1993","unstructured":"Potosky AL, Riley GF, Lubitz JD, Mentnech RM, Kessler LG (1993) Potential for cancer related health services research using a linked Medicare-tumor registry database. Med Care 31(8):732\u2013748","journal-title":"Med Care"},{"issue":"suppl 8","key":"3238_CR22","first-page":"3","volume":"40","author":"JL Warren","year":"2002","unstructured":"Warren JL, Klabunde CN, Schrag D et al (2002) Overview of the SEER-Medicare data: content, research applications, and generalizability to the United States elderly population. Med Care 40(suppl 8):3\u20138","journal-title":"Med Care"},{"key":"3238_CR23","doi-asserted-by":"crossref","unstructured":"Du XL, Goodwin JS (2001) Patterns of use of chemotherapy for breast cancer in older women: findings from Medicare claims data. J Clin Oncol 19:1455\u20131461","DOI":"10.1200\/JCO.2001.19.5.1455"},{"key":"3238_CR24","doi-asserted-by":"crossref","unstructured":"Du XL, Key CR, Dickie L et al (2006) External validation of Medicare claims for breast cancer chemotherapy compared with medical chart reviews. Med Care 44:124\u2013131","DOI":"10.1097\/01.mlr.0000196978.34283.a6"},{"key":"3238_CR25","unstructured":"U.S. Food & Drug Administration (FDA). National Drug Code Directory. \n                    https:\/\/www.accessdata.fda.gov\/scripts\/cder\/ndc\/\n                    \n                  . Accessed August 2016"},{"key":"3238_CR26","unstructured":"Centers for Medicare and Medicaid Services (CMS.gov). (2015) Table of drugs. \n                    https:\/\/www.cms.gov\/Medicare\/Coding\/HCPCSReleaseCodeSets\/Downloads\/2015-Table-of-Drugs-.pdf\n                    \n                  . Accessed August 2016"},{"key":"3238_CR27","doi-asserted-by":"crossref","unstructured":"MacEwan JP, Batt K, Ying W, Peneva D et al (2015) Assessing the economic burden in Medicare patients with multiple myeloma. Blood 126(23)","DOI":"10.1182\/blood.V126.23.2100.2100"},{"key":"3238_CR28","unstructured":"United States, Health Care Financing Administration, Practice Management Information Corporation. (1994) HCPCS 1994 National Level II Medicare Codes: HCFA Common Procedure Coding System. Los Angeles, CA: Practice Manage Information Corp (PMIC)"},{"issue":"5","key":"3238_CR29","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1016\/S0895-4356(99)00011-6","volume":"52","author":"X Du","year":"1999","unstructured":"Du X, Freeman JL, Goodwin JS (1999) Information on radiation treatment in patients with breast cancer: the advantages of the linked Medicare and SEER data. Surveillance, epidemiology and end results. J Clin Epidemiol 52(5):463\u2013470. \n                    https:\/\/doi.org\/10.1016\/S0895-4356(99)00011-6","journal-title":"J Clin Epidemiol"},{"key":"3238_CR30","unstructured":"World Health Organization. (1992\u20131994) WHO Collaborating Centres for Classification of Diseases. International statistical classification of diseases and related health problems. 10th Revised edn. Geneva: World Health Organization"},{"key":"3238_CR31","doi-asserted-by":"crossref","unstructured":"Du XL, Chan W, Giordano S et al (2005) Variation in modes of chemotherapy administration for breast carcinoma and association with hospitalization for chemotherapy-related toxicity. Cancer 104:913\u2013924","DOI":"10.1002\/cncr.21271"},{"issue":"7","key":"3238_CR32","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.1002\/cncr.10825","volume":"95","author":"JS Mandelblatt","year":"2002","unstructured":"Mandelblatt JS, Kerner JF, Hadley J, Hwang YT, Eggert L, Johnson LE, Gold K, For the OPTIONS (Outcomes and Preferences for Treatment in Older Women Nationwide Study) Research Team (2002) Variations in breast cancinoma treatment in older Medicare beneficiaries: is it black or white? Cancer 95(7):1401\u20131414. \n                    https:\/\/doi.org\/10.1002\/cncr.10825","journal-title":"Cancer"},{"key":"3238_CR33","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4757-2555-1","volume-title":"Survival analysis: a self-learning text","author":"DG Kleinbaum","year":"1996","unstructured":"Kleinbaum DG (1996) Survival analysis: a self-learning text. Springer-Verlag, New York. \n                    https:\/\/doi.org\/10.1007\/978-1-4757-2555-1"},{"issue":"1","key":"3238_CR34","doi-asserted-by":"publisher","first-page":"249","DOI":"10.2307\/2533160","volume":"52","author":"DB Rubin","year":"1996","unstructured":"Rubin DB, Thomas N (1996) Matching using estimated propensity scores: relating theory to practice. Biometrics 52(1):249\u2013264. \n                    https:\/\/doi.org\/10.2307\/2533160","journal-title":"Biometrics"},{"key":"3238_CR35","doi-asserted-by":"publisher","first-page":"296","DOI":"10.2307\/2528036","volume":"24","author":"WG Cochran","year":"1968","unstructured":"Cochran WG (1968) The effectiveness of adjustment by subclassification in removing bias in observational studies. Biometrics 24:296\u2013313","journal-title":"Biometrics"},{"issue":"387","key":"3238_CR36","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1080\/01621459.1984.10478078","volume":"79","author":"PR Rosenbaum","year":"1984","unstructured":"Rosenbaum PR, Rubin DB (1984) Reducing bias in observational studies using subclassification on the propensity score. J Am Stat Assoc 79(387):516\u2013524. \n                    https:\/\/doi.org\/10.1080\/01621459.1984.10478078","journal-title":"J Am Stat Assoc"},{"issue":"6","key":"3238_CR37","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.1093\/annonc\/mdu131","volume":"25","author":"L Tong","year":"2014","unstructured":"Tong L, Ahn C, Symanski E, Lai D, Du XL (2014) Effects of newly developed chemotherapy regimens, comorbidities, chemotherapy-related toxicity on the changing patterns of the leading causes of death in elderly patients with colorectal cancer. Ann Oncol 25(6):1234\u20131242. \n                    https:\/\/doi.org\/10.1093\/annonc\/mdu131","journal-title":"Ann Oncol"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00277-018-3238-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-018-3238-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-018-3238-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,16]],"date-time":"2020-05-16T11:12:48Z","timestamp":1589627568000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00277-018-3238-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1,15]]},"references-count":37,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2018,5]]}},"alternative-id":["3238"],"URL":"https:\/\/doi.org\/10.1007\/s00277-018-3238-4","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"type":"print","value":"0939-5555"},{"type":"electronic","value":"1432-0584"}],"subject":[],"published":{"date-parts":[[2018,1,15]]},"assertion":[{"value":"18 May 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 January 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 January 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest statement"}}]}}